20/20 Biolabs Files S-1 for Public Offering

Ticker: AIDX · Form: S-1 · Filed: 2026-04-06T17:28:57-04:00

Sentiment: neutral

Topics: ipo, registration-statement, sec-filing

TL;DR

20/20 Biolabs just filed their S-1, looks like they're going public soon.

AI Summary

20/20 Biolabs, Inc. filed an S-1 registration statement on April 6, 2026. This filing indicates the company is preparing to offer its securities to the public. The filing includes various exhibits such as opinions of counsel and consents from accounting firms, alongside the main registration statement document.

Why It Matters

This S-1 filing is a crucial step for 20/20 Biolabs, Inc. as it signals their intention to become a publicly traded company, potentially opening up new avenues for capital and growth.

Risk Assessment

Risk Level: medium — As an S-1 filing, it represents a company in the process of going public, which inherently carries risks associated with market reception and regulatory scrutiny.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this S-1 filing by 20/20 Biolabs, Inc.?

The primary purpose of the S-1 filing is to register securities with the SEC for a public offering, indicating the company's intent to become publicly traded.

When was this S-1 filing accepted by the SEC?

The S-1 filing was accepted by the SEC on April 6, 2026.

What types of exhibits are included with this S-1 filing?

The filing includes exhibits such as an opinion of counsel (BEVILACQUA PLLC), consent of an accounting firm (DBBMCKENNON), and filing fees, along with the main registration statement.

What does the inclusion of XBRL data files signify?

The XBRL data files (schema, calculation, definition, label, presentation, and instance documents) indicate that the filing contains structured financial data that can be programmatically accessed and analyzed.

What is the SEC Accession Number for this specific filing?

The SEC Accession Number for this filing is 0001213900-26-040553.

Filing Stats: 4,589 words · 18 min read · ~15 pages · Grade level 14 · Accepted 2026-04-06 17:28:57

Key Financial Figures

Filing Documents

Risk Factors

Risk Factors 9 Cautionary Statement Regarding Forward-Looking Statements 26

Use of Proceeds

Use of Proceeds 27 Dividend Policy 27

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 28

Business

Business 39 Management 62

Executive Compensation

Executive Compensation 68 Certain Relationships and Related Party Transactions 72 Principal and Selling Stockholders 73

Description of Capital Stock

Description of Capital Stock 75 Shares Eligible for Future Sale 80 Material U.S. Federal Income Tax Considerations for Non-U.S. Holders 81 Plan of Distribution 85 Legal Matters 86 Experts 86 Where You Can Find More Information 86

Financial Statements

Financial Statements F-1 i You should rely only on the information that we have provided in this prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not authorized anyone to provide you with different information. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus or any related free writing prospectus is accurate only as of the date on the front of this prospectus or any such related free writing prospectus, regardless of the time of delivery of this prospectus or any related free writing prospectus, or any sale of a security. INDUSTRY AND MARKET DATA We are responsible for the disclosure in this prospectus. However, this prospectus includes industry data that we obtained from market research, publicly available information and industry publications. We did not fund and are not otherwise affiliated with any of the sources cited in this prospectus. The market research, publicly available information and industry publications that we use generally state that the information contained therein has been obtained from sources believed to be reliable. The information therein represents the most recently available data from the relevant sources and publications and we believe remains reliable. However, t his data involves a number of assumptions and limitations regarding our industry which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled " Risk Factors ." Forward-looking information o

View on Read The Filing